EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), a leading vision correction service provider in Germany, the PRC and Denmark, is pleased to celebrate its second anniversary of getting listed on the Main Board of Hong Kong Stock Exchange.
In the initial public offering, 79,334,000 offer shares were issued by EuroEyes in an international private placement to institutional investors and a Hong Kong public offering. Trading of the EuroEyes share on the SEHK started on 15 October 2019.
During the past two years, EuroEyes strategically positioned to tap the booming eyecare demands in China and Europe, the Group achieved fast growth. It now runs seven clinics in China covering major cities, with the eighth clinic in Chengdu to commence operation in early 2022. In Germany, the Group also plans to open a new clinic in Wiesbaden. Moreover, the construction of Group’s new flagship clinic in Copenhagen is well in progress, and is anticipated to be completed in 2021 to substitute the Group’s existing clinic in Denmark.
Despite the damaging impact of the unprecedented COVID-19 outbreak on the global economy, EuroEyes has mapped out strategic deployment to look beyond current turbulence by leveraging its leading positions in Germany and Denmark and capitalizing on China’s huge growth potential. For the six months ended 30 June 2021, the Group’s revenue increased by approximately 69.3% YoY to approximately HK$319.7 million. Gross profit increased by approximately 111.4% YoY to HK$159.8 million while gross profit margin stood at approximately 50.0%, representing an YoY increase of 10.0 percentage points. The Group recorded a net profit after tax of approximately HK$65.6 million for the Period, up by 293.2% YoY.
EuroEyes is committed to maintaining a rapid and sustainable development of the Group’s business. To further strengthen the utilization rate of the Group’s existing surgical centres, the Group is expected to establish 10 consultation centres (outpatient clinics without operation theatre) in two years.
Dr.Jørn Slot Jørgensen, the Founder, Chairman and CEO of EuroEyes commented, “I am exited to celebrate our second IPO Anniversary and proud of our endeavour for the past years. Looking ahead, Euroeyes will continue to adopt clear business strategies to maintain rapid and healthy development. We believe that our consultation centre programme will provide synergy effects to our existing clinics, facilitating the Group’s rapid growth in the future. We also believe that the upcoming new surgical clinics in Wiesbaden, Chengdu and Copenhagen will not only expand our business portfolio, but also become new growth engines of the Group. We will continue to leverage our leading position in the industry to capture new market opportunities, especially the acquisition opportunities of high-quality refractive surgical clinics to expand our footprint in Europe while engaging excellent surgeons. We will push forward the acquisition strategy and accelerate the progress when the pandemic situation is eased. We look forward to achieving favourable business growth and continuously create greater value for shareholders.”